ENO1 and cancer: Of note, recent studies have revealed that anti-ENO1 antibody was associated with the CD44+ subpopulation, blocked the malignant transformation of CSCs (Huang et al., 2021; Principe et al., 2015; Shu et al., 2021), and prevented cancer metastasis and prolonged survival (Li et al., 2021).